|
 |
| 1-4
September, 2006 Pragati Maidan, New Delhi, India |
 |
|
|
Ranbaxy Is Eyeing Buyouts In Pathology Labs Business
SRL Ranbaxy is aggressively eyeing acquisitions in the pathology lab business. The pathology testing business of Ranbaxy group has formed a separate team, which is engaged in identifying such acquisition opportunities in both India and abroad.
While its international expansion plan is primarily based on the acquisition of individual labs or regional chains including those located in markets in US and Europe, in the domestic market it is looking at a mix of inorganic and organic expansion.
“We are not constrained by capital and we are looking at labs with all sizes. The idea is to scale up the business from about Rs 1mn now to Rs 5mn by ’10,” says JS Puri, CEO of SRL Ranbaxy.
In the domestic market SRL Ranbaxy has already struck few deals with some standalone pathology labs in West India and is now targeting other regions. The overall plan is to target B class cities.
This apart it is also opening its second clinical reference laboratory in Delhi, which would open by next year. The company is also toying with the idea of expanding its first reference lab, which is located in Mumbai by setting another unit in the city.
As of now SRL Ranbaxy is present in 350 cities and towns across India and abroad with 550 collection centres. While the international clients are, currently, being serviced through the lab in India, the company is also scouting for opportunities in other countries to acquire local resources and testing labs. In addition to this its international expansion programme also includes increased outsourcing contracts.
Date: 28-Jul-2006
Back
|
|
 |
|
|
|
 |
